
Activez les alertes d’offres d’emploi par e-mail !
Générez un CV personnalisé en quelques minutes
Décrochez un entretien et gagnez plus. En savoir plus
A leading research organization in France is seeking a doctoral candidate for a PhD project focusing on the molecular mechanisms of BMP1 inhibition and the development of anti-fibrotic molecules. The role includes hands-on research training across Europe and offers substantial academic and practical experience. Candidates should have a Master's degree in Biochemistry or related fields and proficiency in English. Additional skills in molecular biology and protein analysis are essential.
Organisation/Company: CNRS Department Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique
Research Field: Chemistry » Biochemistry Physics » Biophysics Biological sciences » Biological engineering
Researcher Profile: First Stage Researcher (R1)
Country: France
Application Deadline: 1 Dec 2025 - 00:00 (UTC)
Type of Contract: Temporary
Job Status: Full‑time
Hours Per Week: 35
Offer Starting Date: 1 May 2026
Is the job funded through the EU Research Framework Programme? Horizon Europe - MSCA
Is the Job related to staff position within a Research Infrastructure? No
REMOD‑HEALING is a Doctoral Network funded by the Horizon Europe Programme of the European Union. The REMOD‑HEALING Consortium has funding for 12 full‑time (100%) doctoral scholarships (locations across Europe and Costa Rica) within the context of the recently approved Marie Sklodowska‑Curie Action Doctoral Network (MSCA‑DN).
REMOD‑HEALING is a research network of leading European and Latin American scientists from academia and industry, who want to tackle the burden of pathological wounds by exploiting therapeutic targets and biomarkers associated with extracellular matrix remodelling in cutaneous wounds. Through its research and training activities, the REMOD‑HEALING project will contribute to scientific advancement and innovation in wound healing and regenerative medicine through a coordinated, interdisciplinary effort, ultimately leading to societal and economic benefits (more information coming soon on REMOD‑HEALING website: remod‑healing.eu).
Participating in REMOD‑HEALING offers doctoral candidates many unique opportunities, including:
Several summer/winter schools are also planned to strengthen doctoral students' knowledge in scientific fields, as well as in innovation and transferable skills (scientific communication, intellectual property, writing grant applications, etc.).
The thesis project described here will mainly take place at LBTI (Lyon, France), a laboratory with 120 staff members specializing in cutting‑edge research in tissue biology and in the development of new therapeutic strategies in the field of tissue repair. In addition, the doctoral candidate will experience a 3-week placement at the University of Manchester (UK) in the lab of Clair Baldock for cryo‑electron microscopy training and a 3-month placement at Mimetas (Leiden, The Netherlands) in the lab of Dorota Durek to test an engineered protease inhibitor in an in‑vitro model of skin scarring.
BEFORE APPLYING, PLEASE CHECK THAT YOU MEET THE MOBILITY REQUIREMENTS LISTED IN THE 'CONSTRAINTS AND RISKS' SECTION.
Titre: Elucidation of the molecular basis of BMP1 inhibition by its endogenous inhibitor and development of an anti‑fibrotic molecule
BMP1 (Bone Morphogenetic Protein 1) is an extracellular metalloprotease playing critical roles in extracellular matrix assembly and growth factor activation (1). It is involved in several physiological processes such as development, growth and skin wound healing. The dysregulation of its activity can however lead to pathological conditions, including wound healing disorders (e.g. chronic wounds and scarring). The lab of C. Moali is interested in understanding the mechanisms of regulation of BMP1 activity, at the molecular, cellular and tissue levels, with the goal to develop innovative therapeutic approaches to treat wound healing disorders.
Previous work has shown that BMP1 regulation relies on two main proteins, PCPE1 and PCPE2, with both overlapping and divergent functions. One major difference between the PCPE proteins is that only PCPE2 can inhibit BMP1 proteolytic activity (2, 3). This finding was unexpected because PCPE1 and PCPE2 are very similar in terms of sequences and structures.
The main objectives of the PhD project will be (i) to elucidate the molecular basis of BMP1 inhibition by PCPE2 and (ii) to use this knowledge to design an anti‑fibrotic molecule capable of blocking collagen proteolytic maturation by BMP1.
We will use systematic sequence swapping between PCPE1 and PCPE2 to identify the important residues for PCPE2 inhibitory function (molecular biology, activity assays, surface plasmon resonance). In parallel, we will try to solve the structure of the BMP1/PCPE2 complex by cryo‑electron microscopy with the help of previously developed Nanobodies® to stabilize flexible regions. Finally, we will engineer an optimized inhibitor of BMP1 with high potency, stability and specificity and test its therapeutic potential in a wound‑on‑a‑chip model of skin scarring.
This project will lead to the elucidation of a new mechanism of protease inhibition and to the development of a specific and potent inhibitor of BMP1 with anti‑fibrotic properties.
Additional comments
In addition to the CV and cover letter, the application must include (in a single PDF file attached to the CV):